GGrantIndex
Sort

48,018 grants matching immunotherapy

Biochemical and cellular analysis of regulatory T cells reactive to a natural self antigen

$650,415
Erin June Adams · University Of Chicago · R01 · FY2020 · AI

Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism

$650,406
Nicholas C Denko · Ohio State University · R01 · FY2021 · CA

Novel molecular imaging approaches to monitor gene and cell-based therapies

$650,363
Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2011 · CA

Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials

$650,261
Mourad Tighiouart · Cedars-Sinai Medical Center · U01 · FY2022 · CA

Image-guided ultrasound therapy and drug delivery in pancreatic cancer

$650,148
Katherine W Ferrara · Stanford University · R01 · FY2020 · CA

Exploiting A Critical Vulnerability To Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)

$650,089
Mark Yarchoan · Johns Hopkins University · R01 · FY2024 · CA

Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer

$650,087
Stephen B Gruber · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA

Imaging tumor and T cell responses to metabolic and immune modulation therapy

$650,075
Taha Merghoub · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA

(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer

$650,064
Anna Karolina Palucka · Jackson Laboratory · R01 · FY2019 · CA

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma

$650,020
James Louis Rubenstein · University Of California, San Francisco · R01 · FY2019 · CA

New tools for tracking single cells in vivo

$650,016
Guillem Pratx · Stanford University · R01 · FY2020 · EB

TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES

$650,000
Therapyx, Inc. · R44 · FY2003 · CA

PASSIVE IMMUNITY TO COCAINE USING NOVEL HUMAN ANTIBODIES

$650,000
University Of Cincinnati · U19 · FY2003 · DA

TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory Therapies

$649,938
David R Boulware · University Of Minnesota · R01 · FY2024 · AI

Toward translation of a plant virus-based in situ vaccination nanotechnology

$649,918
Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2022 · CA

Microneedles for treatment of peanut allergy

$649,847
Harvinder Singh Gill · Texas Tech University · R01 · FY2021 · AI

Developing a Translation Pipeline for VHL Mutant Malignancies

$649,803
David McDermott · Beth Israel Deaconess Medical Center · U01 · FY2019 · CA

Characterization of high-grade serous ovarian cancer subtypes via single-cell profiling

$649,725
Casey S Greene · University Of Pennsylvania · R01 · FY2019 · CA

DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to Immunotherapy

$649,712
Karl T Kelsey · Brown University · R01 · FY2023 · CA

Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)

$649,679
Israel Canadas · Research Inst Of Fox Chase Can Ctr · R37 · FY2025 · CA

Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)

$649,679
Israel Canadas · Research Inst Of Fox Chase Can Ctr · R37 · FY2024 · CA

Molecular Allergy

$649,638
Robert E London · National Institute Of Environmental Health Sciences · ZIA · FY2018 · ES

Alteration of skin immune environment by sand fly saliva across progressive Leishmaniasis

$649,558
Christine A Petersen · University Of Iowa · R01 · FY2022 · AI

A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity

$649,506
Benjamin Greenbaum · Sloan-Kettering Inst Can Research · U01 · FY2021 · CA

Understanding Pancreatic Cancer Immune Microenvironment and Treatment Response through Integrating in vivo Imaging with Immunophenotyping

$649,473
Jun Yan · University Of Louisville · R01 · FY2025 · CA